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Background/aim: The protective effects of prostaglandin (PG) analogs on ischemia-reperfusion (I/R) have been well documented;
however, comparative studies are lacking. The aim of the present study was to determine whether iloprost or alprostadil is more effective
in preventing muscle I/R injury.
Materials and methods: Thirty-two rats were divided into four groups (n = 8): sham, control, IL (I/R + iloprost), and AL (I/R +
alprostadil). I/R was induced by a tourniquet in the hindlimb for 3 h/3 h. The IL and AL groups received iloprost (0.5 ng kg–1 min–1) and
alprostadil (0.05 µg kg–1 min–1) during reperfusion, respectively. After 6 h, blood and muscles were collected for analyses.
Results: Serum TNF-α and IL-1β levels were decreased in the IL and AL groups compared with the control group (P < 0.05), whereas
IL-6 levels did not change significantly. Tissue malondialdehyde levels were significantly lower in the IL and AL groups (P < 0.05). Tissue
catalase levels showed no difference. The histological damage scores and apoptosis scores were both significantly decreased in the IL and
AL groups compared with the control group (P< 0.05).
Conclusion: The present study indicated that iloprost and alprostadil attenuated I/R injury in skeletal muscle. However, no comparable
difference was evident regarding the efficacies of either PG analog.
Key words: Ischemia, reperfusion injury, iloprost, alprostadil, skeletal, muscle

1. Introduction
While reestablishing circulation to tissues in an
ischemic state may contribute to their survival, it may
also cause simultaneous damage during reperfusion.
This phenomenon is defined as ischemia-reperfusion
(I/R) injury. I/R injury in skeletal muscle occurs during
revascularization involving the extremities as a result
of both local and systemic inflammatory responses.
Endothelial cells and leukocytes produce chemotactic
cytokines such as tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β), and interleukin-6 (IL-6) following
reperfusion (1). Hypoxic insult and subsequent reperfusion
activate a complex cascade of events involving radical
oxygen species (ROS) production, leukocyte chemotaxis
and adhesion, platelet–leukocyte aggregation, and
increased permeability of microvessels (2). Reestablishing
reperfusion following a long period of ischemia may pose
* Correspondence: atacanemrek@windowslive.com

1028

clinical problems following the revascularization of an
ischemic limb and has a negative impact on both morbidity
and mortality as it can necessitate limb amputation and
cause distant organ injury-related damage (3).
Protective responses are also activated during the
pathophysiological processes associated with I/R injury.
The release of antioxidant enzymes (catalase, superoxide
dismutase, and nitric oxide synthase) and local hormones
such as prostaglandins (PGs) serves as a natural protective
mechanism against I/R injury (4,5). PGI2 and PGE1 are
end-products of arachidonic acid metabolism and are
synthesized primarily by endothelial cells. They inhibit
aggregation of platelets, chemotaxis of inflammatory cells,
and production of ROS (4). Moreover, PGs are potent
vasodilators and regulate microvascular permeability (5).
They are also useful in maintaining tissue microcirculation
by reducing the levels of inflammatory cytokines (TNF-α,
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IL-1β, and IL-6) (1). Although the effects of the two are
similar, it is thought that PGE1 is more potent than PGI2
(6). This difference in modulation of the inflammatory
response depends on different prostanoid receptors of
individual PG mediators (5).
Iloprost and alprostadil are synthetic analogs of PGI2
and PGE1, respectively. Several studies have been reported
concerning the effect of iloprost in the setting of skeletal
muscle ischemic injury (4,7–12). However, less is known
regarding the protective effects of alprostadil on skeletal
muscle following I/R injury (13–15). Comparative studies
regarding the effects of PGs are more scarce in the literature
(6,16). Only one recent study compared the effects of
iloprost and alprostadil on I/R injury (17).
The aim of the present study is to compare the potential
effects of iloprost and alprostadil on the serum levels of
inflammatory cytokines and to explain the logic of PG use
in the prevention of tissue damage and apoptosis in the
setting of acute I/R injury in skeletal muscle.
2. Materials and methods
All research procedures were approved by the animal care
committee of Eskişehir Osmangazi University (Protocol
#325-2/2014) and complied with the ARRIVE (Animal
Research: Reporting of In Vivo Experiments) guidelines.
All experiments were conducted at the Center for Medical
and Surgical Research (TICAM), Eskişehir, Turkey. Until
the day of the experiments, the animals had unlimited
access to standard food pellets and tap water.
Iloprost (Ilomedin, 20 µg/mL) and alprostadil
(Alprostadil, 20 µg/mL) were purchased from Bayer Inc.
(Berlin, Germany) and VEM İlaç Sanayi Ltd. (İstanbul,
Turkey), respectively. The ELISA kits for TNF-α
(Invitrogen, Catalog #KRC3011) and IL-6 (Invitrogen,
Catalog #KRC0061) were purchased from Invitrogen
Corp. (Camarillo, CA, USA), and that for IL-1β (Platinum
ELISA, Catalog #BMS630) was purchased from Bender
MedSystems GmbH (Vienna, Austria). Malondialdehyde
(MDA) and catalase assays were performed in the
Department of Biochemistry. Hematoxylin and eosin and
caspase-3 stainings were performed by Merter Medical
Laboratory Services LTD (Eskişehir, Turkey).
Thirty-two adult female Sprague Dawley rats weighing
250–350 g were used in the study. The animals were divided
randomly into the following four groups (n = 8 each):
sham, control, I/R + iloprost (IL), and I/R + alprostadil
(AL) groups. The sham group was not exposed to I/R
injury and received no treatment. I/R injury was induced
in the control group without treatment. Both the IL and
AL groups were subjected to I/R injury and received the
appropriate drugs. The dosages of iloprost and alprostadil
were based on those used in previous studies (7,8).

2.1. Experimental procedures
The rats were anesthetized with sodium thiopental
(40–50 mg/kg Pental Sodium, İE Ulagay, İstanbul,
Turkey) via intraperitoneal injection. Before beginning
the experimental procedures, 26-gauge polyethylene
catheters were inserted into the right jugular veins for the
administration of a drug or vehicle (0.9% NaCl). Complete
ischemia of the right hindlimb was induced by placing a
tourniquet around the proximal femur in the control, IL,
and AL groups. Following 3 h of ischemia, the tourniquets
were released, and 3 h was allotted for the reperfusion of
the affected limbs. In the IL and AL groups, iloprost (0.5
ng kg–1 min–1) and alprostadil (0.05 µg kg–1 min–1) were
administered via jugular catheters beginning 20 min before
tourniquet release and maintained during the reperfusion
period. The sham and control groups received equal
amounts of vehicle solution. At the end of the reperfusion
period, the gastrocnemius muscles were excised and cut
into three pieces for tissue MDA and catalase analyses, as
well as histopathologic examinations. The animals were
subsequently euthanized via high-volume exsanguination
from the heart. The obtained blood samples were reserved
for IL-1β, IL-6, and TNF-α assays after the serum was
separated via centrifugation at 4000 rpm for 10 min. The
serum and two pieces of muscle were stored at –80 °C
until used for measurements. The last muscle piece was
preserved in a 10% formaldehyde solution.
2.2. Biochemical analysis
Concentrations of immunoreactive TNF-α, IL-1β, and
IL-6 were determined using ELISA kits according to
the manufacturer’s instructions. Briefly, the serum was
reacted with the assay reagents in the TNF-α, IL-1β, and
IL-6 kits and then analyzed spectrophotometrically using
a VICTOR X3 Multilabel Plate Reader (PerkinElmer Inc.,
Waltham, MA, USA) at an absorbance of 450 nm. The
levels of cytokines were calculated using the kit standards
and expressed as pg/mL.
MDA was assayed via a thiobarbituric acid reaction
according to the method devised by Ohkawa et al. (18).
The tissues were homogenized in ice-cold 0.15 mM KCl
buffer using a homogenizer (Ultra Turrax 125-Janke
Kunkol; IKA, Staufen, Germany) and centrifuged at
1000 rpm for 15 min. Equal amounts of supernatant
and 0.5% thiobarbituric acid (w/v) were mixed in 20%
trichloroacetic acid and allowed to react. The absorbance
of the pink-colored thiobarbituric acid reactive substances
was measured using a spectrophotometer (UV-1601;
Shimadzu, Tokyo, Japan) at 532 nM. The levels of tissue
MDA were expressed as nmol/mg.
Catalase was assayed using the Beutler method (19).
After the tissues were homogenized in ice-cold 1 M
phosphate buffer (pH 7) and centrifuged at 600 rpm for
10 min, enzymatic activity based on H2O2 degradation was
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measured using a spectrophotometer at an absorbance of
230 nM. The level of tissue catalase was expressed as U/
mg.
2.3. Histopathological examinations
The muscle specimens placed in 10% formalin were
routinely processed following paraffin embedding. The
sections were sliced at a thickness of 5 µm, stained with
hematoxylin and eosin (H&E), and examined under a light
microscope with a computer connection (Olympus BX50F4, Tokyo, Japan) by a blinded histologist. The histologic
damage in each muscle sample was evaluated quantitatively
in ten visual fields using the following parameters: muscle
fiber degeneration, nuclear centralization, infiltration of the
inflammatory cells, vasocongestion, and disorganization.
The damage was estimated by summing of the parameters
(0 as normal; 1 as mild; 2 as moderate; and 3 as severe).
The lowest score was 0 and the highest score was 15.
The paraffin blocks underwent additional processing for
immunohistochemical evaluation of caspase-3 expression.
Histologic sections of 6 µm in thickness were stained using
the primary cleaved anticaspase-3 (RB-1197-P1) antibody
and antirabbit antibody (Thermo Scientific, Fremont, CA,
USA) according to the manufacturer’s guidelines. The
caspase-3 expression was quantified in a blinded fashion.
Brown-stained myocyte nuclei indicated apoptosis. The
numbers of caspase-positive nuclei per field were counted
to determine the score across ten fields of each muscle
section among all study groups.
2.4. Statistical analysis
The data were analyzed using IBM SPSS 19.0 (IBM
Corp., Armonk, NY, USA). The normal distribution of
continuous variables was assessed by the Shapiro–Wilk
test of normality for compliance within each group. The
normally distributed variables were evaluated by oneway analysis of variance (ANOVA). The nonparametric
Kruskal–Wallis test with the Tukey multiple comparison

test was used for comparisons between the groups due
to the lack of a normal data distribution. The values were
expressed as means ± standard deviations. The significance
level was set at either P < 0.01 or P < 0.05.
3. Results
3.1. Biochemical results
The serum levels of TNF-α and IL-1β were signiﬁcantly
higher in the control group compared with the sham, IL,
and AL groups (P < 0.05). The differences in the TNF-α
and IL-1β levels between the IL and AL groups were not
signiﬁcant. The serum IL-6 level was significantly higher
in the control group compared with the sham group (P <
0.05). However, there was no significant difference in the
IL-6 levels between the IL and AL groups compared with
the control group (Table 1).
The tissue MDA levels were significantly lower in the
sham (5.33 ± 1.33 nmol/mg), IL (7.21 ± 1.66 nmol/mg),
and AL (6.16 ± 1.31 nmol/mg) groups compared with the
control group (10.63 ± 3.66 nmol/mg) (P < 0.05). There
was also a significant difference in MDA levels when the
sham group was compared with the IL and AL groups (P <
0.05). However, no significant difference was found in the
levels of MDA between the IL and AL groups (Figure 1a).
No significant difference in tissue catalase activities was
evident in the sham (66.48 ± 28.64 U/mg), control (120.32
± 51.94 U/mg), IL (104.75 ± 35.39 U/mg), and AL (109.43
± 47.41 U/mg) groups (Figure 1b).
3.2. Histological and immunohistological results
The sham group exhibited almost no damage (Figure
2a). However, severe tissue injury characterized by
inflammatory cell infiltration, vasocongestion, and
disorganization was evident in the control group (Figure
2b). The morphological features of tissue injury were
less evident in the IL and AL groups (Figures 2c and 2d).
The total damage score was significantly elevated in the

Table 1. The serum levels of TNF-α, IL-1β, and IL-6 according to the study groups.
Groups
(pg/mL)

Sham
(n = 8)

Control
(n = 8)

IL
(n = 8)

AL
(n = 8)

P < 0.05

TNF-α*

8.34 ± 1.07

10.86 ± 2.16

8.90 ± 1.50

7.84 ± 2.36

Sham vs. control;
control vs. IL and AL

IL- 1β**

32.02 ± 15.60

61.26 ± 25.63

38.13 ± 10.36

40.99 ± 23.67

Sham vs. control;
control vs. IL and AL

IL -6**

22.83 ± 7.11

35.39 ± 11.08

28.25 ± 7.44

32.77 ± 11.27

Sham vs. control

*: P < 0.05, one-way analysis of variance (ANOVA) for serum TNF-α levels in sham vs, control and control vs. IL and AL. **: P < 0.05,
Kruskal–Wallis one-way ANOVA for IL-1β levels in sham vs. control and control vs. IL and AL. **: P < 0.05 Kruskal–Wallis one-way
ANOVA for IL-6 levels in sham vs. control. IL: Iloprost group, AL: alprostadil group.
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Figure 1. (a) MDA and (b) catalase levels in the skeletal muscle tissues of the rats. *: P < 0.05, Kruskal–Wallis test for tissue MDA levels
in control vs, sham, IL, and AL; sham vs. IL and AL. No significant differences for tissue catalase levels in all groups. IL: Iloprost group,
AL: alprostadil group.

Figure 2. Histologic changes in skeletal muscle sections according to the study groups: (a) normal muscle histology with minimal
changes was demonstrated in the sham group; (b) extensive damage was demonstrated in the control group (I/R); (c, d) the
damage was attenuated in both the IL and AL groups. The arrow indicates muscle fiber degeneration; the arrowhead indicates
inflammatory cell infiltration; vasocongestion is marked with an asterisk. H&E, original magnification 40×. IL: Iloprost group,
AL: alprostadil group.

control group compared with the other groups (P < 0.05).
The difference in total damage scores was not significant

between the IL and AL groups. The scores for each of the
study groups are given in Table 2.
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Table 2. The damage scores according to the study groups. *: P < 0.05, Kruskal–Wallis test, control vs. sham, IL, and AL. IL: Iloprost
group, AL: alprostadil group.
Groups

Sham
(n = 8)

Control
(n = 8)

IL
(n = 8)

AL
(n = 8)

Degeneration

0.25 ± 0.08

1.64 ± 0.07

1.33 ± 0.05

1.64 ± 0.07

Centralization

0.16 ± 0.05

1.05 ± 0.71

0.84 ± 0.13

0.66 ± 0.32

Inflammatory cells

0.26 ± 0.07

1.96 ± 0.12

1.71 ± 0.06

1.27 ± 0.64

Vasocongestion

0.43 ± 0.09

2.64 ± 0.20

1.53 ± 0.07

1.27 ± 0.48

Disorganization

0.15 ± 0.05

2.50 ± 0.12

1.31 ± 0.06

1.31 ± 0.06

Total score

1.25 ± 0.14*

9.79 ± 0.58

6.71 ± 0.54*

5.88 ± 1.47*

The patterns of positive caspase-3 staining among
all of the groups were different (Figures 3a–3d). The
apoptosis scores were significantly elevated in the control
group (3.16 ± 0.07) compared with the sham (1.9 ± 0.06),
IL (1.59 ± 0.08), and AL (1.62 ± 0.09) groups (P < 0.01).
Statistical significance was also evident when the sham
group was compared with the IL and AL groups (P < 0.01).
The difference between the IL and AL groups regarding
apoptosis was not statistically significant (Figure 4).

4. Discussion
Iloprost and alprostadil are commonly used as adjuvant
treatments following revascularization procedures
involving ischemic limbs. Both drugs were retested
for their efficacy in the setting of I/R injury in many
experimental studies (Table 3). However, comparative
studies of iloprost and alprostadil are infrequent in the
literature (6,16,17). The present study compared them
and showed that PG analogs iloprost and alprostadil

Figure 3. Caspase-3 immunostaining study demonstrating apoptosis: (a) no staining was noted in the sham group; (b)
extensive caspase-3 positive staining of myocyte nuclei was noted in the control group; (c, d) caspase-3 staining was decreased
in both the IL and AL groups. The arrow indicates positively stained nuclei (brown) Caspase-3 immunostaining, original
magnification 40×. IL: Iloprost group, AL: alprostadil group.
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Figure 4. Apoptosis scores according to the study groups. *: P < 0.01, Kruskal–Wallis
test, control vs. sham, IL, and AL; sham vs. IL and AL. IL: Iloprost group, AL: alprostadil
group.

were almost equally effective in preventing I/R injury in
skeletal muscle. Iloprost is a stable long-acting analog of
PGI2 and exerts cytoprotective effects mediated by several
possible mechanisms, including vasodilation, membrane
stabilization (7), reduced ROS production, antiplatelet
activity (3,5), increased red cell deformability (20), and
inhibition of leukocyte–endothelial adhesion (1,21). It
also regulates microcirculation by decreasing the levels
of proinflammatory cytokines (1). The effects of iloprost
on injury caused by I/R in skeletal muscle (6–12,17) have
been well documented, but they are still controversial in
the literature. Earlier studies have focused on circulation
research. In an intravital microscopy study, Thomson et
al. demonstrated that iloprost reduced leukocyte-induced
reperfusion injury in extensor digitorum muscle venules
by simulating a femorodistal bypass surgery model (21).
The possible mechanism of action was postulated as
downregulation in the expressions of adhesion molecules
such as ICAM-1 and ELAM-1 in response to iloprost
(1). Blebea et al. demonstrated that iloprost attenuated
increased microvascular permeability in the setting of
I/R injury in rat cremaster muscles (8). However, the
ischemia period utilized in their study was brief and was
characterized by only increased interstitial edema, an
early sign of I/R injury. In 1992, Mohan et al. reported
that the protective effect of iloprost was not related to
the inhibition of neutrophil activation (4). Therefore,
the potential therapeutic role of iloprost remained
undefined until recently. Most recent studies based on
biochemical and histologic findings demonstrated that

iloprost administration attenuated the effects of I/R
injury in skeletal muscle (10–12,17). In clinical practice,
iloprost has been used as an adjuvant to surgery. In a
study involving 192 patients over 70 years of age, iloprost
significantly decreased the combined incidences of death
and amputation; however, it did not delay amputations (3).
In another report, iloprost was found to exert beneficial
effects following the microsurgical repair of arterial
injuries in four infants (22).
Although alprostadil exerts effects similar to those of
iloprost (a PGI2 analog), it (as a PGE1 analog) has been
used less often in the setting of acute skeletal muscle
I/R injury (14,17). The reason for this may be the rapid
metabolism of alprostadil by the lungs, which decreases its
plasma concentrations (23). This may cause less effectivity
in target organs. Antonio et al. (14) and recently Erer et al.
(17) reported that alprostadil did not significantly reduce
inflammatory changes and subsequent muscular damage.
However, alprostadil has been found to be protective in
other organs such as the lungs (17), kidneys (17), and
neural tissue (15). On the contrary, we have found that
alprostadil protected muscle against I/R injury, similar
to iloprost. This finding is supported by other studies.
PGE1 increased the survival of musculocutaneous flaps,
as demonstrated by Hong et al. (13). They chose an
intraflap injection to minimize the adverse effects of PG.
They hypothesized that PGE1 exerts protective effects
against I/R injury by decreasing leukocyte–endothelial cell
adhesion via the decreased expression of ICAM-1. Huk
et al. investigated the role of PGE1 in NO production in
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Table 3. Summary of PG studies on I/R muscle injury.
Authors/reference

Agent(s) or
drug(s)

Time of I/R

Animal, site of injury

Mechanism of action

Conclusion

Belkin et al.,
1990 (7)

Iloprost

6 h/1 h

Dog, gracilis muscle

Not indicated in the article

Preventing muscle I/R injury but no
effect on platelet sequestration

Blebea et al., 1990 (8)

Iloprost

2 h/2 h

Rat, cremaster muscle

Decreasing the rise in vascular permeability

Preventing muscle I/R injury

Mohan et al., 1991 (9)

Iloprost

6 h/48 h

Dog, gracilis muscle

Decreasing leukocyte activity with continuous
infusion

Protective effect on muscle I/R injury
if administered continuously during
reperfusion

Mohan et al., 1992 (4)

Iloprost

6 h/48 h

Dog, gracilis muscle

Leukocyte accumulation or increased microvascular
permeability cannot be inhibited

No protective effect on I/R injury and
muscle necrosis

Rowlands et al.,
1999 (16)

PGE1, PGE2, and
iloprost

6 h/4 h

Rat, hindlimb muscles

Inducing vasodilation

Improving blood flow in I/R muscle
injury

Huk et al., 2000 (24)

PGE1

2.5 h/2 h

Rabbit, adductor magnus
muscle

Indirect reduction of superoxide and peroxynitrite
production to physiological levels

Protective effect on muscle I/R injury

Hong et al., 2001 (13)

PGE1

4 h/5 days

Rat, transverse rectus
abdominis muscle-skin flap

Decreasing leukocyte–endothelial cell adhesion
through decreased expression of ICAM-1

Preventing muscle I/R injury

Bozkurt, 2002 (10)

Iloprost

4 h/1 h

Rat, hindlimb muscles
(gastrocnemius)

Cytoprotection

Preventing muscle I/R injury

Tauber et al., 2004 (6)

PGE1 and PGI2

4 h/24 h

Hamster, dorsal skin striated
muscles

No-reflow and reflow paradox

Attenuation of leukocyte adhesion, but no
effect on microvascular dysfunction

Fräßdorf et al., 2006 (26)

PGE1

3 h/3 h

Rabbit, hindlimb muscles

Positive effect on local hemodynamics (increased
intravascular volume)

Attenuation of I/R injury in terms of
edema formation, but not neuromuscular
function

Emrecan et al., 2008 (11)

Iloprost

2 h/4 h

Rabbit, hindlimb muscles
(gastrocnemius)

Cytoprotection

Preventing muscle I/R injury

Abdel-Rahman et al.,
2009 (25)

PGE1

6 h/90 min

Pig, hindlimb muscles
(gastrocnemius)

Protecting regional blood flow
Increasing serum O2 and glucose consumption
Decreasing muscle ATP consumption

Reducing local hemodynamic effects of
I/R injury in addition to controlled limb
perfusion

Antonio et al.,
2009 (14)

Alprostadil

5 h/1 h

Rat, hindlimb muscles
(gastrocnemius)

Not indicated in the article

No protective effect on muscle I/R injury

Avci et al., 2014 (12)

Iloprost

2 h/2 h

Rat, hindlimb muscles

Cytoprotection

Preventing muscle I/R injury

Erer et al., 2016 (17)

Iloprost and
alprostadil

2 h/2 h

Rat, hindlimb muscles

Not indicated in the article

Preventing muscle I/R injury

the setting of skeletal muscle I/R injury and hypothesized
that there exists an inverse relationship between PGE1
and nitric oxide levels (24). Abdel-Rahman et al. reported
that PGE1 reduced the local hemodynamic effects of I/R
injury in addition to controlling reperfusion, primarily via
the attenuation of the “reflow paradox” (25). However, the
exact effect of PGE1 on I/R injury was not clear, as PGE1
was not used in the setting of uncontrolled reperfusion
in the study in question. Fräßdorf et al. reported that I/R
injury was attenuated by PGE1 treatment, as they observed
decreased edema and creatine kinase release; however,
PGE1 had no influence on the recovery of neuromuscular
function (26). In clinical reports, PGE1 appears to have
yielded more encouraging results regarding its ability to
protect against I/R injury in skeletal muscle (27).
The present study also compared the protective
effects exerted by two synthetic PG analogs, iloprost and
alprostadil, against I/R injury. To evaluate the systemic
response to I/R injury, the levels of three primary
proinflammatory cytokines, TNF-α, IL-1β, and IL-6, were
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assayed in the serum. Iloprost and alprostadil decreased
the levels of both TNF-α and IL-1β; however, they had
no significant effect on the level of IL-6. The local tissue
injury caused by I/R has been assessed by MDA and
catalase assays. MDA is a stable end-product of lipid
peroxidation, which indicates the damage of the cellular
membrane (28). MDA levels, which were increased in
the setting of I/R, were reduced via the administration
of both iloprost and alprostadil. The levels of catalase, a
protective enzyme against ROS, were increased in both
the IL and the AL groups, as well as in the control group.
Therefore, we concluded that the administration of the
PG analogs did not affect tissue protective mechanisms
such as catalase production, but did decrease the extent of
tissue injury. Our histologic examinations demonstrated
that tissue injury was also decreased in both the IL and
AL groups. Inflammatory cell counts, which contributed
primarily to the damage scores, decreased following the
infusion of both PG types. Caspase-3 immunostaining
demonstrated that the apoptosis scores were lower in both
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the IL and AL groups compared with the control group.
Apoptosis is a final determinant of tissue injury, as said
injury often results in programmed cell death. To the best
of our knowledge, this study is the first to demonstrate that
iloprost and alprostadil prevent apoptosis. The possible
role of prostaglandins in decreasing apoptosis can be
investigated in future studies.
Different dosages of iloprost and alprostadil have been
proposed in previous studies to exert maximal protective
effects against I/R injury and exert only minimal adverse
effects (12,14,15,17,25). In light of the currently available
literature, we used 0.5 ng kg–1 min–1 iloprost (12) and 0.05
µg kg–1 min–1 alprostadil (15). The efficacy of both drugs
may change if administered at either higher or lower
doses. Iloprost has a half-life of 30 min and is effective
when administered intravenously (8). It is metabolized in
the kidneys. However, in determining the systemic dose
of alprostadil, it should be taken into consideration that
the plasma concentration of this drug decreases rapidly
following intravenous administration, as the drug may
be metabolized by as much as 80% following a single
pass through the lungs (23). Therefore, alprostadil was
administered at higher doses than iloprost in the present
study. The dosages of the drugs should be higher when
administered systemically as opposed to locally, as is the
case in both femorodistal bypass surgery (21) and flap
surgeries (13). Although hypotension has been reported
following systemic administration (13), we did not observe
deterioration in the health status of the animals during the
experiments.
The present study has a few limitations. First of all,
it showed only early protective effects of the given drugs

on I/R injury. The late effects on I/R injury have not been
demonstrated. The tourniquet use to establish ischemia in
the experiments does not exactly represent ischemia due
to intravascular thrombosis in most clinical scenarios.
The iloprost and alprostadil were not administered in a
combined manner. Therefore, their additive effects are
unknown. Muscle function has not been evaluated with
tests such as electromyography in the current study.
The results of these investigations regarding the effects
of PG analogs against I/R injury in skeletal muscle remain
inconclusive. The protective effects exerted by PGs and
their analogs have been demonstrated in many studies.
However, there have also been studies that found PGs
and their analogs to be less effective in the setting of I/R
injury. In the present study iloprost and alprostadil were
found effective in attenuating I/R injury and reducing
apoptosis in skeletal muscle. However, no significant
difference was found between their efficacies. This result
may guide clinicians in considering adverse effects and
cost-effectiveness in decisions on drug administration.
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